PD25-05 UNDERSTANDING THE ROLE OF STATIN USE ON ADVANCED PROSTATE CANCER OUTCOMES: DOES THE STATIN TYPE, CUMULATIVE DOSE OR DURATION IMPACT SURVIVAL?

Abstract

INTRODUCTION AND OBJECTIVES:There is a growing body of evidence suggesting possible therapeutic role of statin medications on advanced prostate cancer outcomes. However, little is known regarding the impact of the type of statin medications used, the dose of statins received, or the duration of treatment with this class of medications on PCa outcomes. Our goal was to investigate the impact of the statin type, dose and duration on oncologic outcomes in patients with advanced prostate cancer who are treated with androgen deprivation therapy (ADT).METHODS:We used the national VA database to identify all men diagnosed with PCa who are receiving ADT and were treated with statin medications for at least 6 months after PCa diagnosis between 2000 and 2008 with follow-up through May 2016. Patients were then stratified based on the type of statins (hydrophilic vs. lipophilic), the cumulative dose of statins (based on WHO defined daily dose for each statin medication), and the total duration of statins use (< 12 mon...